Data from a phase II trial involving patients with relapsed glioblastoma following chemoradiotherapy, a setting in which few evidence-based therapies are currently available, demonstrate the superiority of the anti-angiogenic tyrosine-kinase inhibitor regorafenib over lomustine chemotherapy. Patients receiving regorafenib had a median overall survival duration of 7.6 months versus 5.6 months in the lomustine group (HR 0.50, 95% CI 0.33–0.75; log-rank P = 0.0009). Grade 3–4 adverse events were more common in the regorafenib group (occurring in 56% versus 40% of patients) and the majority were haematological: decreased platelet count, decreased lymphocyte count and neutropenia were observed in 13%, 13% and 12% of patients, respectively. No treatment-related deaths were reported in either arm. These findings merit further investigation in a randomized phase III trial.
References
Original article
Lombardi, G. et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet https://doi.org/10.1016/S1470-2045(18)30675-2 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Relapsed glioblastomas respond to regorafenib. Nat Rev Clin Oncol 16, 144 (2019). https://doi.org/10.1038/s41571-018-0161-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0161-5